相关实验视频
Updated: Jan 16, 2026

09:42
Comprehensive Analysis of Drug Response using the FLICK Assay
Published on: June 6, 2025
705
药物诱导的农核细胞瘤:不成比例性分析和总体审查
Yajie Lu1,2, Bin Wu1,2, Kunyu Li1,2
1Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Frontiers in pharmacology
|October 3, 2025
概括
这项研究确定了导致药物诱导的血细胞增生症 (DIA) 的药物,这是一种严重的血液疾病. 抗癌药物是最常见的,但其他如抗生素和精神药物也会带来风险,需要临床警.
科学领域:
- 血液学 血液学 血液学
- 药物监督 药物监督 药物监督
- 药品安全 药品安全
背景情况:
- 药物诱导的细胞瘤瘤 (DIA) 是一种罕见但严重的血液病状.
- 增加临床和研究关注对于管理DIA至关重要.
- 这项研究为临床实践提供了DIA的最新概述.
研究的目的:
- 通过使用现实世界的数据来识别与农细胞瘤相关的药物.
- 探索混因素和DIA的发病时间.
- 通过对现有文献的系统审查来补充发现.
主要方法:
- 对FDA不良事件报告系统 (FAERS) 数据的不成比例性分析.
- 对DIA风险因素和时间进行后勤和时间开始分析.
- 对DIA系统性审查的总体审查.
主要成果:
- 抗癌药物,包括甲基和莱纳利多米德,最常与DIA相关.
- 高风险药物,年龄较大和体重异常与DIA有关.
- 克洛扎的中位发病时间最长,而阿齐思罗米辛的中位发病时间最短.
结论:
- 广泛的药物,主要是抗癌药物,与DIA有关.
- 非化疗药物也会导致DIA风险.
- 提高临床警和进一步研究监测策略至关重要.
更多相关视频
相关概念视频
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
232
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
232
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
208
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
208
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Drug Regulation
2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
149
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
149
Dosage Regimen: Individualization
166
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
166

